Results 41 to 50 of about 728 (161)

Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. [PDF]

Circulation
BACKGROUND: Post-exercise oxygen uptake recovery (VO₂Rec) is slow in advanced heart failure. We sought to establish easily derived VO₂Rec measures and evaluate their cardiospecificity and prognostic relevance in patients with dyspnea on exertion.
Campain J, Griskowitz C, Newlands C, Claggett BL, Kulac IJ, McGinnis S, Giverts I, Moreno F, Minasian A, Prasad C, Rupert L, Landsteiner I, Iskenderian N, Coats CJ, Lee MMY, Maron MS, Owens AT, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Malhotra R, Lewis GD.   +23 more
europepmc   +3 more sources

Magnetic resonance imaging evaluation of the effects of myosin inhibitors (mavacamten and aficamten) in hypertrophic cardiomyopathy: a systematic review and case report

Monaldi Archives for Chest Disease
Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder, affecting approximately 1 in 250 individuals. It is defined by unexplained left ventricular (LV) hypertrophy in the absence of other identifiable cardiac or systemic causes.
Carolina Bernardes, João Gomes Carvalho, Patrícia Rodrigues, Manuela França   +3 more
doaj   +2 more sources

Myosin inhibitors for treatment of hypertrophic cardiomyopathy. [PDF]

Cochrane Database Syst Rev
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:/ / Primary objective: To assess the effects of myosin inhibitors compared to usual care or placebo on exercise capacity, need for septal reduction ...
Quill S, Amin AS, Asselbergs FW, Bezzina C, Elliott PM, van der Velden J, Schmidt AF.   +6 more
europepmc   +3 more sources

Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities [PDF]

Biomedicines
Hypertrophic cardiomyopathy (HCM) is often associated with left ventricular outflow tract (LVOT) obstruction, which affects a substantial proportion of patients.
Marco Maria Dicorato, Gaetano Citarelli, Francesco Mangini, Rossella Alemanni, Miriam Albanese, Sebastiano Cicco, Cosimo Angelo Greco, Cinzia Forleo, Paolo Basile, Maria Cristina Carella, Marco Matteo Ciccone, Andrea Igoren Guaricci, Ilaria Dentamaro   +12 more
doaj   +2 more sources

Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM

Journal of the American College of Cardiology
BACKGROUND Standard-of-care (SoC) medications for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) are recommended as first-line therapy despite the lack of evidence from controlled clinical trials and well known off-target side effects.
Ahmad Masri, Roberto Barriales Villa, Artur Oreziak   +2 more
exaly   +2 more sources

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy [PDF]

, 2023
Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy
Olivotto, Iacopo
core   +4 more sources

Precision medicine in complex diseases—Molecular subgrouping for improved prediction and treatment stratification

Journal of Internal Medicine, Volume 294, Issue 4, Page 378-396, October 2023., 2023
Abstract Complex diseases are caused by a combination of genetic, lifestyle, and environmental factors and comprise common noncommunicable diseases, including allergies, cardiovascular disease, and psychiatric and metabolic disorders. More than 25% of Europeans suffer from a complex disease, and together these diseases account for 70% of all deaths ...
Åsa Johansson, Ole A. Andreassen, Søren Brunak, Paul W. Franks, Harald Hedman, Ruth J. F. Loos, Benjamin Meder, Erik Melén, Craig E. Wheelock, Bo Jacobsson   +9 more
wiley   +1 more source

A pathogenic nonsense mutation (c.1522C>T) of the MYBPC3 gene is implicated with hypertrophic cardiomyopathy

ESC Heart Failure, Volume 10, Issue 4, Page 2711-2717, August 2023., 2023
Abstract Hypertrophic cardiomyopathy (HCM), a genetically and clinically heterogeneous cardiomyopathy, is commonly caused by mutations in the MYBPC3 gene or other various sarcomeric genes. HCM patients carrying sarcomeric gene mutations may experience an asymptomatic period at early stage but still possess an escalating risk of developing adverse ...
Erru Ni, Tao Wang, Xuan Zhang, Huabin Xie   +3 more
wiley   +1 more source

A New Chapter in the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors [PDF]

, 2023
In the recent years, there has been a significant breakthrough in the treatment of hypertrophic cardiomyopathy. New precision molecules have been developed and successfully applied in clinical trials. A new class of orally available allosteric inhibitors
Olivotto Iacopo, Pálinkás Eszter Dalma, Sepp Róbert   +2 more
core   +1 more source

Pharmacokinetics of a single dose of Aficamten (CK‐274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model

Journal of Veterinary Pharmacology and Therapeutics, Volume 46, Issue 1, Page 52-61, January 2023., 2023
Abstract Hypertrophic cardiomyopathy (HCM) is the most prevalent cardiac disease in cats and lacks efficacious preclinical pharmacologic intervention, prompting investigation of novel therapies. Genetic mutations encoding sarcomeric proteins are implicated in the development of HCM and small molecule myosin inhibitors are an emerging class of ...
Ashley N. Sharpe, Maureen S. Oldach, Joanna L. Kaplan, Victor Rivas, Samantha L. Kovacs, Darren T. Hwee, Bradley P. Morgan, Fady I. Malik, Samantha P. Harris, Joshua A. Stern   +9 more
wiley   +1 more source